Retreatment of Exudative Age-Related Macular Degeneration after Loading 3-Monthly Intravitreal Ranibizumab

@article{Sugiyama2017RetreatmentOE,
  title={Retreatment of Exudative Age-Related Macular Degeneration after Loading 3-Monthly Intravitreal Ranibizumab},
  author={Atsushi Sugiyama and Yoichi Sakurada and S. Honda and A. Miki and Wataru Matsumiya and Seigo Yoneyama and Wataru Kikushima and H. Iijima},
  journal={Ophthalmologica},
  year={2017},
  volume={239},
  pages={52 - 59}
}
Purpose: The aim of this study was to investigate the clinical implications of required retreatment after 3-monthly intravitreal ranibizumab (IVR) injections followed by as-needed reinjections up to 5 years in eyes with exudative age-related macular degeneration (AMD). Methods: A retrospective cohort study was conducted for 165 treatment-naïve eyes from 165 patients with exudative AMD. Visual changes were investigated in terms of the required retreatments. Results: Retreatment-free proportions… Expand

References

SHOWING 1-10 OF 29 REFERENCES
Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
...
1
2
3
...